Michel Sadelain, MD, PhD, a CAR-T therapy innovator and one of the world's top immunologists, has left New York City-based Memorial Sloan Kettering Cancer Center for two new roles at Columbia University Irving Medical Center, also in New York City.
Columbia named Dr. Sadelain director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center and the first director of the new Columbia Initiative in Cell Engineering and Therapy, according to a Sept. 30 news release from Columbia.
Dr. Sadelain founded the Center for Cell Engineering at Memorial Sloan Kettering in 2007, where he led the development of CAR-T cells to target specific markers found in certain blood cancer cells.